两种新的中性粒细胞亚群定义脓毒症的鉴别特征
本研究旨在寻找能早期、特异鉴别脓毒症与非感染性炎症综合征的免疫细胞标志物。采用质谱流式技术检测全血免疫细胞42种标记,并结合高维数据分析,在脓毒症患者中发现了CD64+不成熟中性粒细胞内两个新亚群,由CD123和PD-L1表达区分。这些不成熟中性粒细胞活化和吞噬功能减弱,且CD123表达中性粒细胞比例与临床严重程度相关。结论提示该7标记流式方案可区分脓毒症与其他炎症状态,但尚需临床验证。
要点
- 在脓毒症患者全血中,CD64+不成熟中性粒细胞存在两个新亚群,由CD123和PD-L1表达区分。
- 这些不成熟中性粒细胞表现出活化和吞噬功能减弱。
- CD123表达中性粒细胞的比例与脓毒症临床严重程度相关。
- 该脓毒症特征可通过常规流式细胞术检测7种标记实现,不与其他炎症生物标志物重叠。
- 该发现尚属生物学里程碑,能否立即改善患者 care 需进一步验证。
适用人群与场景
- 成人ICU脓毒症患者与对照受试者(包括非感染性炎症综合征患者)。
- 原文未提及具体纳入/排除标准、样本量及研究中心数。
诊断标准与关键阈值
- 原文未提及脓毒症诊断的具体临床标准或评分界值。
- 两个新中性粒细胞亚群定义为CD64+不成熟中性粒细胞中CD123和PD-L1表达不同的亚群。
处置流程与药物剂量
- 原文未提及基于该生物标志物的具体治疗流程或药物剂量。
红旗征与不能漏的情况
- 原文未提及需要立刻处理或不能漏诊的红旗征。
研究设计与关键结果
- 研究类型:观察性研究(采用质谱流式结合高维计算分析),原文未明确样本量与中心数。
- 人群:脓毒症患者与对照受试者(包括非感染性炎症综合征)。
- 方法:检测全血免疫细胞42种标记,无监督分析高维质谱流式数据。
- 关键发现:鉴定出两个新的不成熟中性粒细胞亚群,由CD123和PD-L1表达区分,这些细胞活化和吞噬功能减弱。
- CD123表达中性粒细胞比例与临床严重程度相关。
- 结论:该7标记流式方案可区分脓毒症与其他炎症状态。
证据类型、等级与局限
- 证据类型:观察性研究(质谱流式和高维分析),原文未明确证据等级或推荐强度。
- 局限:原文未提及样本量、单中心或多中心、是否前瞻性验证;结论称可立即转化但需进一步临床验证。
对床旁实践的改变
- 原文提示可用7种标记的常规流式细胞术检测两种中性粒细胞亚群,以辅助鉴别脓毒症与非感染性炎症综合征;但原文未提供具体操作阈值、适用人群限制或临床决策流程,尚不能改变现有急诊/ICU实践。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Rationale: Sepsis is the leading cause of death in adult ICUs. At present, sepsis diagnosis relies on nonspecific clinical features. It could transform clinical care to have immune-cell biomarkers that could predict sepsis diagnosis and guide treatment. For decades, neutrophil phenotypes have been studied in sepsis, but a diagnostic cell subset has yet to be identified. Objectives: To identify an early, specific immune signature of sepsis severity that does not overlap with other inflammatory biomarkers and that distinguishes patients with sepsis from those with noninfectious inflammatory syndrome. Methods: Mass cytometry combined with computational high-dimensional data analysis was used to measure 42 markers on whole-blood immune cells from patients with sepsis and control subjects and to automatically and comprehensively characterize circulating immune cells, which enables identification of novel, disease-specific cellular signatures. Measurements and Main Results: Unsupervised analysis of high-dimensional mass cytometry data characterized previously unappreciated heterogeneity within the CD64+ immature neutrophils and revealed two new subsets distinguished by CD123 and PD-L1 (programmed death ligand 1) expression. These immature neutrophils exhibited diminished activation and phagocytosis functions. The proportion of CD123-expressing neutrophils correlated with clinical severity. Conclusions: This study showed that these two new neutrophil subsets were specific to sepsis and detectable through routine flow cytometry by using seven markers. The demonstration here that a simple blood test distinguishes sepsis from other inflammatory conditions represents a key biological milestone that can be immediately translated into improvements in patient care.
参考来源
- Meghraoui-Kheddar, Chousterman, Guillou, et al. Two New Neutrophil Subsets Define a Discriminating Sepsis Signature. Am J Respir Crit Care Med. 2022. PMID: 34731593. doi:10.1164/rccm.202104-1027OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。